Skip to main content

Table 1 Clinical characteristics of the eligible patients

From: Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy

Characteristics

TCC ≤ 7 (N = 169)

 

TCC ≥ 8 (N = 219)

 

COD <  460 mg/m2 (N = 73)

COD ≥ 460 mg/m2 (N = 96)

P value

COD < 720 mg/m2 (N = 90)

COD ≥ 720 mg/m2 (N = 129)

P value

Age / years old

≥ 55

44 (60.3%)

55 (57.3%)

0.697

45 (50.0%)

51 (39.5%)

0.125

< 55

29 (39.7%)

41 (42.7%)

 

45 (50.0%)

78 (60.5%)

 

Gender

Male

46 (63.0%)

71 (74.0%)

0.127

63 (70.0%)

78 (60.5%)

0.147

Female

27 (37.0%)

25 (26.0%)

 

27 (30.0%)

51 (39.5%)

 

Anemia

Yes

26 (35.6%)

27 (28.1%)

0.298

33 (36.7%)

35 (27.1%)

0.134

No

47 (64.4%)

69 (71.9%)

 

57 (63.3%)

94 (72.9%)

 

Differentiation

Poor

11 (16.7%)

12 (12.9%)

0.506

8 (8.9%)

20 (15.5%)

0.149

Moderate-good

62 (83.3%)

84 (87.1%)

 

82 (91.1%)

109 (84.5%)

 

CEA / ng/ml

≥ 5

36 (49.3%)

39 (46.0%)

0.260

42 (46.7%)

56 (43.4%)

0.634

< 5

37 (50.7%)

57 (54.0%)

 

48 (53.3%)

73 (56.6%)

 

CA19–9 / U/ml

≥ 35

18 (24.7%)

15 (15.6%)

0.581

11 (12.2%)

23 (17.8%)

0.260

<  35

55 (75.3%)

81 (84.4%)

 

79 (87.8%)

106 (82.2%)

 

Clinical stage

cIII

47 (64.4%)

73 (76.0%)

0.098

71 (78.9%)

112 (86.8%)

0.119

cII

26 (35.6%)

23 (24.0%)

 

19 (21.1%)

17 (13.2%)

 
  1. Abbreviations: TCC Total chemotherapy cycle, COD Cumulative oxaliplatin dose, CEA Carcinoembryonic antigen, CA19–9 Carbohydrate antigen 19–9